melanotan II comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-03-27. Where a claim depends on a specific study, the study is described rather than over-claimed.
Melanotan II is a synthetic cyclic heptapeptide that acts as an agonist at melanocortin receptors. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous peptide involved in pigment production. The analogue carries a lactam bridge that constrains the ring and slows enzymatic breakdown relative to the native hormone. In research literature it appears under several abbreviations, and naming conventions are not fully standardized. Published descriptions usually place it within the broader melanocortin agonist family.
Receptor binding at MC1R on melanocytes raises intracellular cyclic AMP and increases expression of tyrosinase and related enzymes. The downstream result is greater synthesis of eumelanin, the dark pigment, without ultraviolet exposure acting as the trigger. The compound is not selective, however, and also engages MC3R, MC4R and MC5R, which are expressed in the central nervous system and elsewhere. That lack of selectivity is the explanation usually offered for effects reported outside pigmentation, including appetite suppression and nausea. Selectivity remains a central theme in comparative studies of related peptides.
Human data remain limited and mostly short-term. Reports describe small trials and observational accounts rather than large controlled studies, so questions about dose-response relationships and long-term effects on melanocytes stay open. Whether repeated exposure alters naevus behaviour is not settled in the published record. Researchers also note that self-administered use outside clinical settings makes actual exposure difficult to quantify. Statements about efficacy and safety should therefore be read as preliminary rather than established.
Regulatory treatment of this peptide varies by country. It holds no marketing authorization as a medicine in the United States, the European Union, or most other jurisdictions. Some countries classify products containing it as prescription-only or unlicensed medicines, which restricts lawful supply. Authorities have issued public notices warning that unregulated products may contain undeclared or incorrect ingredients. The molecule also appears on prohibited lists for competitive sport. These measures address supply oversight rather than any approved therapeutic role.
Published research on the compound remains limited. Much of the human data comes from small, early-stage studies rather than large controlled trials, and several questions about effects and variability between individuals remain open. Investigators have examined receptor activity, pigment pathways, and related physiological responses in laboratory and animal models. Findings from those models do not automatically translate to human outcomes. Reviews frequently note the scarcity of rigorous clinical evidence and call for better-characterized study material.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic cyclic heptapeptide | Melanocortin receptor agonist |
| Molecular formula | C50H69N15O9 | Neutral form, mass near 1024.2 g/mol |
| Primary targets | MC1R, MC3R, MC4R, MC5R | Binding is non-selective across subtypes |
| Related compounds | Alpha-MSH, melanotan I, afamelanotide | Structurally or functionally related peptides |
| Common abbreviations | MT-II, MT-2 | Naming in the literature is not uniform |
Melanotan-2 is a synthetic linear peptide built from seven amino acids arranged in a short chain. Its sequence is commonly written as Ac-Nle-Asp-His-D-Phe-Arg-Trp-Lys-NH2, which includes a modified N-terminus and an amidated C-terminus. The molecule belongs to the melanocortin family and acts as a receptor agonist. Structural features such as the D-phenylalanine residue and the Nle substitution are associated with increased stability against enzymatic degradation relative to the natural parent peptide.
The compound emerged from research programs in the 1980s that examined analogues of alpha-melanocyte-stimulating hormone for pigmentation and photoprotection. Investigators modified the native sequence to extend activity duration and potency. A related analogue, afamelanotide, was developed within the same broad line of inquiry and eventually gained approval in certain jurisdictions for a rare light-sensitivity condition. Melanotan-2 itself did not progress through the same regulatory route and has no approved therapeutic indication.
Quality assessment of research-grade peptide rests mainly on reversed-phase high-performance liquid chromatography for purity and on mass spectrometry for identity confirmation. A single main peak above a stated threshold, commonly ninety-eight percent by peak area, is the usual release criterion applied by suppliers. Independent analyses commissioned by laboratories and consumer organisations have repeatedly reported discrepancies between label claims and measured content, including truncated sequences, residual trifluoroacetate, and lower-than-declared peptide mass. Those findings do not establish that every supplier is unreliable, but they indicate that purity figures printed on a vial are claims requiring verification rather than settled facts.
Regulatory treatment varies by jurisdiction and has changed over time. In several countries the peptide is handled as an unapproved prescription medicine, and import or sale for human use is restricted, while elsewhere it falls under poisons or controlled-substance schedules. Enforcement activity against online vendors has been reported in Australia, New Zealand, the United Kingdom and the United States. Scholarly writing discusses melanotan-2 chiefly as an experimental tool and as a case study in unregulated peptide supply, and its precise legal position in any given country should be checked against current national schedules.
Melanotan II is a synthetic cyclic heptapeptide analog derived from the core sequence of alpha-melanocyte-stimulating hormone. Researchers at the University of Arizona synthesized it during the 1980s while studying pigmentation and appetite signaling. The compound is not an approved medicine in any major jurisdiction and appears mainly in laboratory and research-chemical settings. Its structure incorporates a lactam bridge between side chains, which constrains the ring and slows enzymatic breakdown relative to the natural hormone.
Melanotan II binds several melanocortin receptor subtypes rather than a single target. MC1R on melanocytes drives melanin synthesis, while MC3R and MC4R participate in energy balance, appetite, and sexual response pathways. This lack of selectivity explains why reported effects extend beyond skin darkening. Substitutions at positions four and seven, including norleucine and D-phenylalanine, increase potency and resistance to peptidases. Understanding which receptor mediates which effect remains an active area of investigation.
Published human data come mostly from small, short studies rather than large controlled trials. Reported outcomes include increased skin pigmentation and, in some reports, effects on appetite and libido, but sample sizes are small and follow-up is limited. Whether long-term use produces durable pigment changes or adverse effects is not established. Because products sold outside pharmacies are not standardized, the actual content of any given vial is often unknown. Independent testing of such material is uncommon.
Food in Hong Kong is primarily based on Cantonese cuisine, despite the territory's exposure to foreign influences and its residents' varied origins. Rice is the staple food, and is usually served plain with other dishes. Freshness of ingredients is emphasised. Poultry and seafood are commonly sold live at wet markets, and ingredients are used as quickly as possible when still fresh. There are up to five daily meals: breakfast, lunch, afternoon tea, dinner, and siu yeh. Dim sum, as part of yum cha (brunch), is a dining-out tradition with family and friends. Dishes include congee, cha siu bao, siu yuk, egg tarts, and mango pudding. Local versions of Western food are served at cha chaan teng (Hong Kong-style cafes). Common cha chaan teng menu items include macaroni in soup, deep-fried French toast, and Hong Kong-style milk tea. As of 2025, the Michelin Guide listed 76 starred restaurants in total. It awarded 7 restaurants 3 Michelin Stars, 11 restaurants with 2 Michelin Stars, and 58 restaurants with 1 Michelin Star. It also gave 4 Green Stars for sustainability, Amber, Feuille, Mora, and Roganic. Alongside the starred list, 65 restaurants received Bib Gourmand status for good quality food at good value.
=== United States === Cannabis tea is scheduled at the federal level in the United States by nature of being a derivative of Cannabis sativa, and it is therefore illegal to possess, buy, and sell. Due to variances in statewide laws, and the reluctance of the federal government to overrule the states, however, the federal legislation has little impact on nationwide use, and is "generally applied only against persons who possess, cultivate, or distribute large quantities of cannabis". As such, regulation of recreational and/or medicinal growth and use on an individual level is not the responsibility of the federal government.
=== Antioxidant capacity of chocolate and hops === The phenolic antioxidants for cocoa powder, dark chocolate, and milk chocolate can also be determined via cyclic voltammetry. In order to achieve this, the anodic peaks are calculated and analyzed with the knowledge that the first and third anodic peaks can be assigned to the first and second oxidation of flavonoids, while the second anodic peak represents phenolic acids. Using the graph produced by cyclic voltammetry, the total phenolic and flavonoid content can be deduced in each of the three samples. It was observed that cocoa powder and dark chocolate had the highest antioxidant capacity since they had high total phenolic and flavonoid content. Milk chocolate had the lowest capacity as it had the lowest phenolic and flavonoid content. While the antioxidant content was given using the cyclic voltammetry anodic peaks, HPLC must then be used to determine the purity of catechins and procyanidin in cocoa powder, dark chocolate, and milk chocolate. Hops, the flowers used in making beer, contain antioxidant properties due to the presence of flavonoids and other polyphenolic compounds. In this cyclic voltammetry experiment, the working electrode voltage was determined using a ferricinium/ferrocene reference electrode. By comparing different hop extract samples, it was observed that the sample containing polyphenols that were oxidized at less positive potentials proved to have better antioxidant capacity.
Sources: en.wikipedia.org
=== Hi–Hu === Evelyn Hickmans] (1883–1972). British biochemist, pioneer in treatment of phenylketonuria Archibald Vivian Hill FRS (1886–1977). British protein biophysicist at University College London known primarily for work in muscle biochemistry, but also for the Hill equation, still widely used for quantifying protein cooperativity. Nobel Prize in Physiology or Medicine (1922). Robin Hill FRS (1899–1991). British plant biochemist at the University of Cambridge who demonstrated the Hill reaction of photosynthesis. Frank Hird (1920–2014). Australian agricultural biochemist at the University of Melbourne. Dorothy Hodgkin FRS (1910–1994). British X-ray crystallographer at the University of Oxford, pioneer in protein crystallography. Nobel Prize in Chemistry (1964) Jan-Hendrik S. Hofmeyr (b. 1953). South African biochemist at the University of Stellenbosch active in metabolic control analysis. Kenneth Charles Holmes FRS (1934–2021), British molecular biologist and a pioneer in using synchrotron X-ray radiation Mei Hong (born 1970). Chinese-American biophysical chemist known for development solid-state nuclear magnetic resonance to elucidate the structures and mechanisms of membrane proteins Nick Hoogenraad (active from 1969). Australian biochemist, discoverer of the mechanism of the mitochondrial unfolded protein response, Professor of Biochemistry at La Trobe University (1993–2014). Frederick Gowland Hopkins FRS (President) (1861–1947). British biochemist at Cambridge University who discovered tryptophan and worked on vitamins.
== NeuCode SILAC == Traditionally the level of multiplexing in SILAC was limited due to the number of SILAC isotopes available. Recently, a new technique called NeuCode (neutron encoding) SILAC, has augmented the level of multiplexing achievable with metabolic labeling (up to 4). The NeuCode amino acid method is similar to SILAC but differs in that the labeling only utilizes heavy amino acids. The use of only heavy amino acids eliminates the need for 100% incorporation of amino acids needed for SILAC. The increased multiplexing capability of NeuCode amino acids is from the use of mass defects from extra neutrons in the stable isotopes. These small mass differences however need to be resolved on high-resolution mass spectrometers.
That certain ascomycetes and basidiomycetes are missing RNAi pathways indicates that proteins required for RNA silencing have been lost independently from many fungal lineages, possibly due to the evolution of a novel pathway with similar function, or to the lack of selective advantage in certain niches.
Sources: en.wikipedia.org
== Early and personal life == Epstein was born in the Bronx, New York, and is Jewish. His parents were Jack (a salesman, born in Toronto, Ontario, Canada) and Evelyn (born in New York City). When he was three years old, his family moved to Hartsdale, New York, and then when he was 13 to the Fairfax District in Los Angeles, California. Epstein said of his father, who refused when Epstein was still a minor to sign a contract on his behalf with the Dodgers: "He wanted me to be a lawyer, rather than a bum."
== History == KNX-100 was first described in the scientific literature by 2012. It was originated at the University of Sydney by Iain McGregor and Michael Bowen and colleagues and is under development by Kinoxis Therapeutics in partnership with Boehringer Ingelheim. In 2018, it was reported that KNX-100 had been under development for more than a decade. The drug was identified via a phenotypic screen of compounds derived from a fragment-based drug discovery system targeting the oxytocin system. In January 2026, it was disclosed that KNX-100's mechanism of action is inhibition of the enzyme arachidonate 15-lipoxygenase (ALOX15).
The organisation was formed by the BSAC in 1889 as a paramilitary, mounted infantry force in order to provide protection for the Pioneer Column of settlers which moved into Mashonaland in 1890. In common with several colonial police forces such as the Royal Canadian Mounted Police (RCMP), it was modelled on the Royal Irish Constabulary (RIC), and its early officers were trained at the Police Depot in the Phoenix Park in Dublin. The unit played a central role in both the First Matabele War (1893) and the Second Matabele War (1896/97) with many troopers serving in the Jameson Raid. Until 1896 the force was called the British South Africa Company's Police. The BSAP operated originally in conjunction with the Southern Rhodesia Constabulary (SRC), the town police force for Salisbury (now Harare) and Bulawayo, but amalgamated with the SRC in 1909.
=== Basicity === Pyridines are Bronsted base and Lewis bases. The pKa values of their protonated forms are between 9.5 and 15.5. Comparatively strong bases include 2,3-diaminopyridine (pKS value of the protonated form: 15.26) and 2,4,6-collidine (15.0). Rather weak bases include 3-chloropyridine (9.56) and 2-methoxypyridine (9.94). For the base pyridine itself, the value of 12.53 lies in the middle of this range. The pKS values are similar for protonated 2-methylpyridine (13.28) and 2,2'-bipyridine (12.27). Pyridine is significantly less basic than the structurally related but saturated piperidine.
Sources: en.wikipedia.org
It is a synthetic cyclic heptapeptide and a non-selective melanocortin receptor agonist. Structurally it is modelled on alpha-melanocyte-stimulating hormone, a peptide that occurs naturally in the body.
Activation of MC1R increases pigment synthesis independently of ultraviolet exposure, which is the mechanism usually cited for darkening without sun exposure. Ultraviolet light still influences skin response through separate biological pathways.
Because the peptide binds several melanocortin receptor subtypes, its effects are not confined to pigmentation. This complicates interpretation of both intended and unintended outcomes reported in studies.
Only a small number of early-stage human studies have been reported, and most were limited in size and duration. No large late-stage program has established a general efficacy or safety profile. The evidence base is therefore thin compared with approved medicines.